La catena delle opzioni mostra i dati chiave delle opzioni azionarie di OceanaGold Philippines a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per OceanaGold Philippines..

OceanaGold Philippines (OTC:OGCIF) Azioni, Catena delle Opzioni

OceanaGold Philippines Inc produces gold and copper in the Philippines and is a subsidiary of OceanaGold Corporation. The company operates the Didipio gold and copper mine located in the northern Luzon region of the Philippines which is the Didipio Mine, approximately two hundred seventy km north-northeast of Metro Manila.

OCEANAGOLD (PHILIPPINES) by OCEANAGOLD (PHILIPPINES) INC.

OceanaGold Philippines Inc

HC Wainwright &amp; Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) with a Buy and maintains $40 price target.

News

Price Target

Reiteration

Analyst Ratings

OKUR

HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $40 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy and lowers the price target from $6 to $5.

RLYB

HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $5

<a href="https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales">https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales</a>
&nbsp;
Toyota Motor Corp.'s North American chief operating officer criticized the US's policies promoting speedy adoption of electric vehicles, calling them "de facto mandates" out of sync with consumer demand.

Management

Global

'Toyota Executive Lashes Out At U.S. Regulations Promoting EV Sales' - Bloomberg News

Needham analyst Chris Pierce maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Buy and raises the price target from $27 to $39.

CARG

Needham Maintains Buy on CarGurus, Raises Price Target to $39

Barclays analyst Benjamin Budish maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Overweight and raises the price target from $50 to $57.

Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $57

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Barclays analyst Jared Shaw maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and raises the price target from $56 to $64.

Barclays Maintains Overweight on Synovus Finl, Raises Price Target to $64

Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/MSI/earnings">FY24 adjusted EPS guidance above estimates on Thursday.</a>
Motorola Solutions reported quarterly earnings of $3.74 per share which beat the analyst consensus estimate of $3.38 per share. The company reported quarterly sales of $2.79 billion which beat the analyst consensus estimate of $2.76 billion.
&#8220;Our third-quarter results were exceptional, with record Q3 revenue, earnings and cash flow,&#8221; said Greg Brown, chairman and CEO, Motorola Solutions. &#8220;We achieved strong growth across the board, and I&#8217;m pleased with the momentum of our business. As a result, we&#8217;re again raising our revenue and earnings expectations for the full year.&#8221;
Motorola Solutions shares gained 6.8% to trade at $501.80 on Friday.
These analysts made changes to their price targets on Motorola Solutions following earnings announcement.
<ul>
<li>Raymond James analyst Adam Tindle maintained Motorola with an Outperform and raised the price target from $425 to $515.</li>
<li>Barclays analyst Tim Long maintained the stock with an Overweight and raised the price target from $467 to $529.</li>
</ul>
Considering buying MSI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png" alt="" class="wp-image-638367" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

Markets

Trading Ideas

These Analysts Raise Their Forecasts On Motorola Solutions Following Q3 Earnings

HC Wainwright &amp; Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) with a Buy and maintains $13 price target.

TNGX

HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Underweight and raises the price target from $245 to $255.

Barclays Maintains Underweight on Rockwell Automation, Raises Price Target to $255

WIIM

Canopy Growth shares are trading lower. The company reported Q2 financial results.

<a href="https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion">https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion</a>
The National Highway Traffic Safety Administration (NHTSA) voiced concerns about Tesla's social media messaging concerning its Full Self-Driving (FSD) software.
NHTSA's worry stems from Tesla's implications that their FSD can be used as a robotaxi, negating the need for constant driver attention. This issue has elevated in importance following an investigation the agency initiated in October into 2.4 million Tesla vehicles equiped with FSD software.
The inquiry came after four reported accidents, including a fatal crash this year. In an email from May 14 released publicly, the NHTSA criticized Tesla's social media announcements for potentially misleading the public into viewing the FSD as anything other than a driver assist system demanding vigilant supervision and occasional driver intervention.

Legal

TSLA

"The National Highway Traffic Safety Administration Expressed Concerns Regarding Tesla's Social Media Posts That Imply Its Full Self-Driving Software Can Function As A Robotaxi Without Driver Supervision. This Comes After The NHTSA Opened An Investigation Into Tesla's FSD Software Following Four Collisions, Including A Fatal Crash In 2023." - Dev Discourse

HC Wainwright &amp; Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Buy and raises the price target from $19 to $20.

RLAY

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $20

MNMD

Mind Medicine shares are trading higher after the company reported better-than-expected Q3 EPS results.

PRQR

ProQR Therapeutics shares are trading higher afer HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $5 to $10.

Needham analyst Laura Martin reiterates Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Buy and maintains $6 price target.

Needham Reiterates Buy on Outbrain, Maintains $6 Price Target

Over the past 24 hours, Injective's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/inj/usd">INJ</a>) price rose 4.88% to $22.66. This continues its positive trend over the past week where it has experienced a 20.0% gain, moving from $18.77 to its current price. As it stands right now, the coin's all-time high is $52.62. 
The chart below compares the price movement and volatility for Injective over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092546_0.png" alt="price_chart" />
The trading volume for the coin has increased 55.0% over the past week while the overall circulating supply of the coin has increased 0.0% to over 97.73 million. The current market cap ranking for INJ is #50 at $2.21 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092546_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$INJ

Cryptocurrency Injective Rises More Than 4% In 24 hours

ACHR

Archer Aviation shares are trading higher after the company reported better-than-expected Q3 EPS results.

Barclays analyst Adrienne Yih maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $200 to $257.

Barclays Maintains Overweight on Ralph Lauren, Raises Price Target to $257

ESPR

Esperion Therapeutics shares are trading higher. The stock may be moving on continued strength after reporting better-than-expected Q3 financing results yesterday. Also, HC Wainwright & Co. reiterated a Buy rating on the stock.

Comments

OceanaGold Philippines

OceanaGold Philippines (OGCIF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO